Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.
Elghawy O, et al. Among authors: sun l.
Clin Lung Cancer. 2024 Dec 13:S1525-7304(24)00263-8. doi: 10.1016/j.cllc.2024.11.014. Online ahead of print.
Clin Lung Cancer. 2024.
PMID: 39743378
No abstract available.